A phase III will be set up, like a building permit, but there's no way we're going to build. Way to expensive. As reported earlier a deal is predicted in 2H 2017 to then commence trials in 2018.
It was conservatively estimated at $650m.
If we run a self funded trial with more help from LW then pharma will have to fork out billions post phase III.
As an aside, because best effect was seen at 200 (what ever the units were) compared to lower doses in the trial and earlier trials does that mean revenue forecasts increase pro-rata??
Lemmings of the cliff., page-17
-
- There are more pages in this discussion • 176 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.14 |
Change
1.150(5.48%) |
Mkt cap ! $2.829B | |||
| Open | High | Low | Value | Volume |
| $21.50 | $22.44 | $21.50 | $13.15M | 598.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 437 | $22.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.15 | 8325 | 7 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |